Abstract
The α7 nicotinic acetylcholine receptors (nAChRs), ligand-gated Ca2+ channels composed of homopentamers of α7 subunits, represent the most abundant with α4β2 nAChRs in the brain. Several lines of evidence suggest that α7 nAChRs play a role in the physiology of neuropsychiatric diseases such as schizophrenia, Alzheimer's disease, anxiety, depression, and drug addiction; hence, α7 nAChRs seem to be attractive therapeutic targets for these diseases. Several researchers have attempted to develop radioligands that can be used to selectively and quantitatively examine the distribution of α7 nAChRs in the human brain with positron emission tomography (PET) or single photon emission tomography (SPECT). Although efforts are underway, very low density of α7 nAChR and scarcity of very high affinity ligands hamper the development of α7 subtype-selective radioligands for in vivo imaging. In this article, we review the recent topics on the development of PET/SPECT ligands for in vivo imaging of α7 nAChRs in the brain.
Keywords: nicotinic acetylcholine receptors, positron emission tomography (PET), single photon emission tomography (SPECT), schizophrenia, Alzheimer’s disease.
Current Topics in Medicinal Chemistry
Title:Recent Development of Radioligands for Imaging α7 Nicotinic Acetylcholine Receptors in the Brain
Volume: 10 Issue: 15
Author(s): Jun Toyohara, Jin Wu and Kenji Hashimoto
Affiliation:
Keywords: nicotinic acetylcholine receptors, positron emission tomography (PET), single photon emission tomography (SPECT), schizophrenia, Alzheimer’s disease.
Abstract: The α7 nicotinic acetylcholine receptors (nAChRs), ligand-gated Ca2+ channels composed of homopentamers of α7 subunits, represent the most abundant with α4β2 nAChRs in the brain. Several lines of evidence suggest that α7 nAChRs play a role in the physiology of neuropsychiatric diseases such as schizophrenia, Alzheimer's disease, anxiety, depression, and drug addiction; hence, α7 nAChRs seem to be attractive therapeutic targets for these diseases. Several researchers have attempted to develop radioligands that can be used to selectively and quantitatively examine the distribution of α7 nAChRs in the human brain with positron emission tomography (PET) or single photon emission tomography (SPECT). Although efforts are underway, very low density of α7 nAChR and scarcity of very high affinity ligands hamper the development of α7 subtype-selective radioligands for in vivo imaging. In this article, we review the recent topics on the development of PET/SPECT ligands for in vivo imaging of α7 nAChRs in the brain.
Export Options
About this article
Cite this article as:
Toyohara Jun, Wu Jin and Hashimoto Kenji, Recent Development of Radioligands for Imaging α7 Nicotinic Acetylcholine Receptors in the Brain, Current Topics in Medicinal Chemistry 2010; 10 (15) . https://dx.doi.org/10.2174/156802610793176828
DOI https://dx.doi.org/10.2174/156802610793176828 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics The Role of Glutamate and its Receptors in Migraine
CNS & Neurological Disorders - Drug Targets The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target
Current Pharmaceutical Design Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Radiotracers for Amyloid Imaging in Neurodegenerative Disease: State-of-the-Art and Novel Concepts
Current Medicinal Chemistry Hrd1 Facilitates Tau Degradation and Promotes Neuron Survival
Current Molecular Medicine Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research MicroRNA-10b Induces Vascular Muscle Cell Proliferation Through Akt Pathway by Targeting TIP30
Current Vascular Pharmacology Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases
Current Protein & Peptide Science Evaluation of a Dramatic Writing Workshop in Youth With or Without Psychiatric Disorders
Adolescent Psychiatry Bifunctional Anti-HIV/TB Inhibitors: Perspective from In-Silico Design and Molecular Dynamics Simulations
Letters in Drug Design & Discovery Pharmacokinetic Properties and In Silico ADME Modeling in Drug Discovery
Medicinal Chemistry Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Current Drug Targets - CNS & Neurological Disorders Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine